Docetaxel-loaded PEG-albumin nanoparticles with improved antitumor efficiency against non-small cell lung cancer.
The aim of the present study was mainly to assess the advantage of docetaxel-loaded PEG-albumin nanoparticles (PEG-DANPs) against non-small cell lung cancer (NSCLC) compared with the commercial product of docetaxel (Aisu®) and docetaxel-albumin nanoparticles (DANPs). We made systematic assessments on these three drugs against NSCLC both in vitro and in vivo. Based on our experiments, PEG-DANPs showed a dose- and time-dependent efficacy in the in vitro cytotoxicity studies; the tumors growth and the metastases in the livers of NSCLC-bearing nude mice in vivo were reduced dmarkedly by PEG-DANPs, and the PEG-DANP-treated mice had a minimum of weight loss; furthermore, the mice which were treated with PEG-DANPs can survive longer than the other groups. In conclusion, the PEG-DANPs have the lowest side-effects, and the highest antitumor and metastases activity of the three drugs, and it may provide an alternative to patients with NSCLC.
Yanbian University Hospital, Yanji, Jilin 133000, P.R. China.
Guangming
G
Jin
State Key Laboratory of Bioactive Substance and Functions of Natural Medicines, Beijing Key Laboratory of Drug Delivery Technology and Novel Formulations, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100050, P.R. China.
Mingji
M
Jin
Yanbian University Hospital, Yanji, Jilin 133000, P.R. China.
Zhehu
Z
Jin
State Key Laboratory of Bioactive Substance and Functions of Natural Medicines, Beijing Key Laboratory of Drug Delivery Technology and Novel Formulations, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100050, P.R. China.
Zhonggao
Z
Gao
Yanbian University Hospital, Yanji, Jilin 133000, P.R. China.
Xuezhe
X
Yin
D000072283:A549 Cells; D000418:Albumins / Q000737:chemistry*; D000818:Animals; D000970:Antineoplastic Agents / Q000737:chemistry / Q000494:pharmacology*; D002289:Carcinoma, Non-Small-Cell Lung / Q000188:drug therapy*; D045744:Cell Line, Tumor; D000077143:Docetaxel; D004337:Drug Carriers / Q000737:chemistry; D005260:Female; D006801:Humans; D008175:Lung Neoplasms / Q000188:drug therapy*; D008297:Male; D051379:Mice; D008807:Mice, Inbred BALB C; D008819:Mice, Nude; D053758:Nanoparticles / Q000008:administration & dosage* / Q000737:chemistry; D011092:Polyethylene Glycols / Q000737:chemistry*; D043823:Taxoids / Q000737:chemistry / Q000494:pharmacology*; D023041:Xenograft Model Antitumor Assays / Q000379:methods
D000418:Albumins; D000970:Antineoplastic Agents; D004337:Drug Carriers; D043823:Taxoids; D000077143:Docetaxel; D011092:Polyethylene Glycols